Tarsus Pharmaceuticals, Inc. TARS License fees and collaboration revenue — Total revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s license fees and collaboration revenue — total revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s license fees and collaboration revenue — total revenues?
- Tarsus Pharmaceuticals, Inc. (TARS) reported license fees and collaboration revenue — total revenues of $16.67M in Q1 2026.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s license fees and collaboration revenue — total revenues?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s license fees and collaboration revenue — total revenues has grown at a -100.0% compound annual growth rate (CAGR), from $25.82M to $0.
- What does license fees and collaboration revenue — total revenues mean?
- This metric represents the total revenue recognized from licensing intellectual property, milestone payments, and collaborative research agreements within a specific business segment. It reflects the company's ability to monetize its proprietary technology and drug development pipeline through strategic partnerships rather than direct product sales. High revenue in this category indicates successful commercialization of research assets through external alliances.